Literature DB >> 22982398

Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease.

Chaoyun Li1, Azadeh Ebrahimi, Hermann Schluesener.   

Abstract

Alzheimer's disease (AD) is one of the most important neurodegenerative disorders, bringing about huge medical and social burden in the elderly worldwide. Many aspects of its pathogenesis have remained unclear and no effective treatment exists for it. Within the past 20 years, various mice models harboring AD-related human mutations have been produced. These models imitate diverse AD-related pathologies and have been used for basic and therapeutic investigations in AD. In this regard, there are a wide variety of preclinical trials of potential therapeutic modalities using AD mice models which are of paramount importance for future clinical trials and applications. This review summarizes more than 140 substances and treatment modalities being used in transgenic AD mice models from 2001 to 2011. We also discuss advantages and disadvantages of each model to be used in therapeutic development for AD.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982398     DOI: 10.1016/j.arr.2012.09.002

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  13 in total

Review 1.  Alzheimer's in 3D culture: challenges and perspectives.

Authors:  Carla D'Avanzo; Jenna Aronson; Young Hye Kim; Se Hoon Choi; Rudolph E Tanzi; Doo Yeon Kim
Journal:  Bioessays       Date:  2015-08-07       Impact factor: 4.345

Review 2.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

3.  Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease.

Authors:  William A Beltran; Artur V Cideciyan; Simone Iwabe; Malgorzata Swider; Mychajlo S Kosyk; Kendra McDaid; Inna Martynyuk; Gui-Shuang Ying; James Shaffer; Wen-Tao Deng; Sanford L Boye; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

4.  Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease.

Authors:  Benjamin J Bell; Medhinee M Malvankar; Carolyn Tallon; Barbara S Slusher
Journal:  ACS Chem Neurosci       Date:  2020-10-13       Impact factor: 4.418

5.  Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

Authors:  Jeffrey L Cummings; Travis Morstorf; Kate Zhong
Journal:  Alzheimers Res Ther       Date:  2014-07-03       Impact factor: 6.982

Review 6.  Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in Search of a Relevant Mechanism.

Authors:  Paweł Grieb
Journal:  Mol Neurobiol       Date:  2015-03-07       Impact factor: 5.590

Review 7.  The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind.

Authors:  Roberta Ricciarelli; Ernesto Fedele
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

8.  A Toxic Conformer of Aβ42 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease.

Authors:  Naotaka Izuo; Chihiro Kasahara; Kazuma Murakami; Toshiaki Kume; Masahiro Maeda; Kazuhiro Irie; Koutaro Yokote; Takahiko Shimizu
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

9.  A New Approach to Model Sporadic Alzheimer's Disease by Intracerebroventricular Streptozotocin Injection in APP/PS1 Mice.

Authors:  Sally Kelliny; Liying Lin; Isaac Deng; Jing Xiong; Fiona Zhou; Mohammed Al-Hawwas; Larisa Bobrovskaya; Xin-Fu Zhou
Journal:  Mol Neurobiol       Date:  2021-04-02       Impact factor: 5.590

10.  Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease.

Authors:  Michael A Castello; John David Jeppson; Salvador Soriano
Journal:  BMC Neurol       Date:  2014-09-02       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.